Drug Profile

UX 016

Alternative Names: Sialic Acid-C16 Prodrug; UX-016

Latest Information Update: 29 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ultragenyx Pharmaceutical
Class Fatty acids; Sialic acids; Small molecules
Mechanism of Action Glycosylation modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Nonaka distal myopathy

Most Recent Events

01 Apr 2026 Ultragenyx Pharmaceutical has patent protection for UX 016 in USA
01 Apr 2026 Ultragenyx Pharmaceutical has patents pending for UX 016 in USA
30 Mar 2026 Preclinical trials in Nonaka distal myopathy in USA (SC)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com